MGAM2
gene geneOn this page
Summary
MGAM2 (maltase-glucoamylase 2 (putative), HGNC:28101) is a protein-coding gene on chromosome 7q34, encoding Probable maltase-glucoamylase 2 (Q2M2H8).
Predicted to enable alpha-1,4-glucosidase activity. Predicted to be involved in carbohydrate metabolic process. Predicted to be located in membrane.
Source: NCBI Gene 93432 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 2 total
- Druggable target: yes — 4 molecules with ChEMBL bioactivity
- MANE Select transcript:
NM_001293626
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:28101 |
| Approved symbol | MGAM2 |
| Name | maltase-glucoamylase 2 (putative) |
| Location | 7q34 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000257743 |
| Ensembl biotype | protein_coding |
| Entrez | 93432 |
Gene structure
Transcript identifiers
Ensembl transcripts: 3 — 2 protein_coding, 1 retained_intron
ENST00000477922, ENST00000496337, ENST00000550469
RefSeq mRNA: 1 — MANE Select: NM_001293626
NM_001293626
CCDS: CCDS78281
Canonical transcript exons
ENST00000477922 — 48 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001830641 | 142144861 | 142144945 |
| ENSE00001842198 | 142161955 | 142162004 |
| ENSE00001848979 | 142157937 | 142158091 |
| ENSE00001866098 | 142167268 | 142167486 |
| ENSE00001866548 | 142160134 | 142160258 |
| ENSE00001878708 | 142159287 | 142159343 |
| ENSE00001901066 | 142158248 | 142158332 |
| ENSE00001903692 | 142166098 | 142166253 |
| ENSE00001916607 | 142143769 | 142143882 |
| ENSE00001917086 | 142154018 | 142154189 |
| ENSE00001918800 | 142164856 | 142165023 |
| ENSE00001922281 | 142154729 | 142154845 |
| ENSE00001924392 | 142161125 | 142161213 |
| ENSE00001952749 | 142147456 | 142147573 |
| ENSE00002336693 | 142137433 | 142137545 |
| ENSE00002347662 | 142120302 | 142120381 |
| ENSE00002348872 | 142116874 | 142116979 |
| ENSE00002356119 | 142130948 | 142131071 |
| ENSE00002376012 | 142136541 | 142136640 |
| ENSE00002382131 | 142138542 | 142138667 |
| ENSE00002405043 | 142140802 | 142140933 |
| ENSE00002414307 | 142133981 | 142134152 |
| ENSE00002422367 | 142131931 | 142132085 |
| ENSE00002424919 | 142131518 | 142131627 |
| ENSE00002425158 | 142141021 | 142141119 |
| ENSE00002445209 | 142171272 | 142171440 |
| ENSE00002487327 | 142170075 | 142170229 |
| ENSE00003293922 | 142219870 | 142222324 |
| ENSE00003428216 | 142111718 | 142111807 |
| ENSE00003476071 | 142172652 | 142172764 |
| ENSE00003486883 | 142185077 | 142185139 |
| ENSE00003498531 | 142208573 | 142208622 |
| ENSE00003502902 | 142196700 | 142196816 |
| ENSE00003505642 | 142173229 | 142173354 |
| ENSE00003510316 | 142218361 | 142218531 |
| ENSE00003520320 | 142198139 | 142198195 |
| ENSE00003521072 | 142198615 | 142198739 |
| ENSE00003532958 | 142196154 | 142196287 |
| ENSE00003535321 | 142183266 | 142183373 |
| ENSE00003536821 | 142185989 | 142186123 |
| ENSE00003538133 | 142175652 | 142175780 |
| ENSE00003552794 | 142189367 | 142189505 |
| ENSE00003578802 | 142196565 | 142196599 |
| ENSE00003600371 | 142197400 | 142197548 |
| ENSE00003650243 | 142197644 | 142197728 |
| ENSE00003658818 | 142199880 | 142199968 |
| ENSE00003666053 | 142187750 | 142187834 |
| ENSE00003683019 | 142172098 | 142172194 |
Expression profiles
Bgee: expression breadth broad, 66 present calls, max score 90.29.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.6238 / max 221.9893, expressed in 48 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 81573 | 0.3358 | 40 |
| 81574 | 0.2881 | 22 |
Top tissues by expression
116 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| duodenum | UBERON:0002114 | 90.29 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 77.36 | gold quality |
| body of pancreas | UBERON:0001150 | 73.33 | gold quality |
| small intestine | UBERON:0002108 | 72.32 | gold quality |
| pancreas | UBERON:0001264 | 72.21 | gold quality |
| sural nerve | UBERON:0015488 | 71.46 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 71.45 | gold quality |
| islet of Langerhans | UBERON:0000006 | 71.43 | gold quality |
| saliva-secreting gland | UBERON:0001044 | 70.60 | gold quality |
| blood | UBERON:0000178 | 70.41 | gold quality |
| minor salivary gland | UBERON:0001830 | 69.65 | gold quality |
| rectum | UBERON:0001052 | 69.18 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 66.19 | gold quality |
| tonsil | UBERON:0002372 | 64.05 | gold quality |
| vermiform appendix | UBERON:0001154 | 62.34 | gold quality |
| gall bladder | UBERON:0002110 | 61.07 | gold quality |
| transverse colon | UBERON:0001157 | 58.69 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 57.66 | gold quality |
| left testis | UBERON:0004533 | 57.47 | gold quality |
| intestine | UBERON:0000160 | 57.40 | gold quality |
| testis | UBERON:0000473 | 57.35 | gold quality |
| tibial nerve | UBERON:0001323 | 56.15 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 55.54 | gold quality |
| right testis | UBERON:0004534 | 55.40 | gold quality |
| bone marrow | UBERON:0002371 | 54.76 | gold quality |
| spleen | UBERON:0002106 | 54.35 | gold quality |
| bone marrow cell | CL:0002092 | 54.25 | gold quality |
| ventricular zone | UBERON:0003053 | 51.16 | silver quality |
| colon | UBERON:0001155 | 50.90 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 49.14 | gold quality |
Single-cell (SCXA)
Detected in 3 experiment(s), a significant marker in 3.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-7 | yes | 90.57 |
| E-ENAD-21 | yes | 90.57 |
| E-ANND-3 | yes | 4.52 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
18 targeting MGAM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-9-5P | 100.00 | 72.28 | 2361 |
| HSA-MIR-3667-3P | 99.99 | 67.17 | 1636 |
| HSA-MIR-548AW | 99.99 | 72.57 | 3559 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-1468-3P | 99.96 | 72.74 | 3797 |
| HSA-MIR-570-3P | 99.96 | 72.41 | 4910 |
| HSA-MIR-3686 | 99.90 | 70.53 | 2432 |
| HSA-MIR-7162-3P | 99.89 | 68.16 | 1682 |
| HSA-MIR-6507-5P | 99.36 | 70.46 | 2524 |
| HSA-MIR-4711-3P | 98.97 | 66.87 | 1020 |
| HSA-MIR-4684-3P | 98.24 | 69.91 | 1075 |
| HSA-MIR-6747-3P | 97.73 | 64.84 | 1596 |
| HSA-MIR-562 | 97.66 | 65.63 | 698 |
| HSA-MIR-4288 | 97.11 | 67.23 | 1636 |
| HSA-MIR-4662A-3P | 97.02 | 67.77 | 941 |
| HSA-MIR-656-5P | 96.82 | 67.67 | 372 |
| HSA-MIR-632 | 96.08 | 67.17 | 798 |
| HSA-MIR-758-5P | 93.99 | 64.46 | 534 |
Cross-species orthologs
9 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | si:ch211-236l14.4 | ENSDARG00000062059 |
| danio_rerio | gaa2 | ENSDARG00000074282 |
| danio_rerio | ENSDARG00000104569 | |
| mus_musculus | Mgam2-ps | ENSMUSG00000102802 |
| rattus_norvegicus | Mgam2 | ENSRNOG00000066165 |
| drosophila_melanogaster | GCS2alpha | FBGN0027588 |
| drosophila_melanogaster | tobi | FBGN0261575 |
| caenorhabditis_elegans | WBGENE00018682 | |
| caenorhabditis_elegans | WBGENE00019895 |
Paralogs (6): GANAB (ENSG00000089597), SI (ENSG00000090402), MYORG (ENSG00000164976), GAA (ENSG00000171298), GANC (ENSG00000214013), MGAM (ENSG00000257335)
Protein
Protein identifiers
Probable maltase-glucoamylase 2 — Q2M2H8 (reviewed: Q2M2H8)
Alternative names: Maltase-glucoamylase (alpha-glucosidase) pseudogene
All UniProt accessions (1): Q2M2H8
UniProt curated annotations — full annotation on UniProt →
Subcellular location. Membrane.
Similarity. Belongs to the glycosyl hydrolase 31 family.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q2M2H8-1 | 1 | yes |
| Q2M2H8-3 | 2 |
RefSeq proteins (1): NP_001280555* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000322 | Glyco_hydro_31_TIM | Domain |
| IPR000519 | P_trefoil_dom | Domain |
| IPR011013 | Gal_mutarotase_sf_dom | Homologous_superfamily |
| IPR013780 | Glyco_hydro_b | Homologous_superfamily |
| IPR017853 | GH_hydrolase_sf | Homologous_superfamily |
| IPR025887 | Glyco_hydro_31_N_dom | Domain |
| IPR030458 | Glyco_hydro_31_AS | Active_site |
| IPR044913 | P_trefoil_dom_sf | Homologous_superfamily |
| IPR048395 | Glyco_hydro_31_C | Domain |
Pfam: PF00088, PF01055, PF13802, PF21365
UniProt features (32 total): disulfide bond 6, region of interest 5, active site 4, glycosylation site 4, topological domain 2, compositionally biased region 2, modified residue 2, splice variant 2, domain 2, chain 1, transmembrane region 1, sequence conflict 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q2M2H8-F1 | 76.60 | 0.60 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (4): 478 (nucleophile); 481; 1375 (nucleophile); 1378
Post-translational modifications (2): 371, 1238
Disulfide bonds (6): 43–72, 54–71, 65–84, 608–619, 916–933, 928–946
Glycosylation sites (4): 167, 421, 613, 2249
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 33 (showing top):
GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_CATABOLIC_PROCESS, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_CATABOLIC_PROCESS, GOCC_APICAL_PART_OF_CELL, GOMF_GLUCOSIDASE_ACTIVITY, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_GLYCOSYL_BONDS, GOMF_HYDROLASE_ACTIVITY_HYDROLYZING_O_GLYCOSYL_COMPOUNDS, GOBP_DISACCHARIDE_METABOLIC_PROCESS, GOMF_ALPHA_GLUCOSIDASE_ACTIVITY, OISHI_CHOLANGIOMA_STEM_CELL_LIKE_DN, DLX2_TARGET_GENES, SOX10_TARGET_GENES, ZNF350_TARGET_GENES, MIR4288
GO Biological Process (2): disaccharide catabolic process (GO:0046352), carbohydrate metabolic process (GO:0005975)
GO Molecular Function (8): glucan 1,4-alpha-glucosidase activity (GO:0004339), alpha-1,4-glucosidase activity (GO:0004558), carbohydrate binding (GO:0030246), catalytic activity (GO:0003824), hydrolase activity, hydrolyzing O-glycosyl compounds (GO:0004553), hydrolase activity (GO:0016787), hydrolase activity, acting on glycosyl bonds (GO:0016798), alpha-glucosidase activity (GO:0090599)
GO Cellular Component (5): cytoplasm (GO:0005737), plasma membrane (GO:0005886), endomembrane system (GO:0012505), apical part of cell (GO:0045177), membrane (GO:0016020)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 4 |
| alpha-glucosidase activity | 2 |
| disaccharide metabolic process | 1 |
| oligosaccharide catabolic process | 1 |
| primary metabolic process | 1 |
| binding | 1 |
| molecular_function | 1 |
| hydrolase activity, acting on glycosyl bonds | 1 |
| catalytic activity | 1 |
| hydrolase activity | 1 |
| glucosidase activity | 1 |
| intracellular anatomical structure | 1 |
| membrane | 1 |
| cell periphery | 1 |
| vacuole | 1 |
| plasma membrane | 1 |
Protein interactions and networks
STRING
1584 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MGAM2 | AMY1B | P04745 | 986 |
| MGAM2 | AMY2B | P19961 | 986 |
| MGAM2 | AMY2A | P04746 | 985 |
| MGAM2 | MGAM | O43451 | 857 |
| MGAM2 | TBXAS1 | P24557 | 822 |
| MGAM2 | HAO1 | Q9UJM8 | 753 |
| MGAM2 | TREH | O43280 | 734 |
| MGAM2 | LCT | P09848 | 623 |
| MGAM2 | MEP1A | Q16819 | 511 |
| MGAM2 | MEP1B | Q16820 | 507 |
| MGAM2 | TNFRSF11B | O00300 | 497 |
| MGAM2 | GLB1 | P16278 | 445 |
| MGAM2 | TAS1R3 | Q7RTX0 | 443 |
| MGAM2 | MAN2C1 | Q9NTJ4 | 443 |
| MGAM2 | SI | P14410 | 427 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MGAM2 | SMC4 | psi-mi:“MI:0915”(physical association) | 0.400 |
| NRAS | IGKV2D-24 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (4): LOC93432 (Affinity Capture-MS), LOC93432 (Affinity Capture-MS), SMC4 (Proximity Label-MS), NSRP1 (Cross-Linking-MS (XL-MS))
ESM2 similar proteins: A0A6J2ATK2, A5HUI5, A6QPT7, D3UW23, M3XFH7, O57579, O88917, O88923, O94910, O95490, O97817, O97827, O97831, P15144, P15145, P15541, P15684, P16406, P42658, P42659, P46101, P50123, P79098, P79143, P79171, P97449, P97629, Q07075, Q10737, Q22523, Q2KHK3, Q2M2H8, Q32LQ0, Q5RFP3, Q6P179, Q6Q4G3, Q7Q2T8, Q7TT41, Q80TR1, Q80TS3
Diamond homologs: A1CNK4, A1D1E6, B0XNL6, B8MZ41, D4B0X3, F4J6T7, O00906, O04893, O04931, O43451, O62653, O74254, P07768, P10253, P14410, P22861, P23739, P29064, P56526, P70699, Q09901, Q0CMA7, Q12558, Q2M2H8, Q2UQV7, Q43763, Q4WRH9, Q5AWI5, Q5R7A9, Q653V7, Q6P7A9, Q92442, Q9C0Y4, Q9MYM4, Q9S7Y7, Q9URX4, P19965, Q9P999, Q8RQU9, Q69ZQ1
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
2 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 1 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
6160 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 7:142116869:TCTA:T | acceptor_loss | 1.0000 |
| 7:142116870:CTA:C | acceptor_loss | 1.0000 |
| 7:142116871:TA:T | acceptor_loss | 1.0000 |
| 7:142116872:A:AG | acceptor_gain | 1.0000 |
| 7:142116872:AGAT:A | acceptor_gain | 1.0000 |
| 7:142116873:G:GG | acceptor_gain | 1.0000 |
| 7:142116873:GAT:G | acceptor_gain | 1.0000 |
| 7:142116873:GATG:G | acceptor_gain | 1.0000 |
| 7:142116975:TTCAG:T | donor_loss | 1.0000 |
| 7:142116976:TCAG:T | donor_loss | 1.0000 |
| 7:142116977:CAGG:C | donor_loss | 1.0000 |
| 7:142116978:AG:A | donor_loss | 1.0000 |
| 7:142116980:G:C | donor_loss | 1.0000 |
| 7:142116981:T:A | donor_loss | 1.0000 |
| 7:142120370:G:GT | donor_gain | 1.0000 |
| 7:142130945:CA:C | acceptor_loss | 1.0000 |
| 7:142130946:A:AC | acceptor_loss | 1.0000 |
| 7:142130946:A:AG | acceptor_gain | 1.0000 |
| 7:142130946:AG:A | acceptor_gain | 1.0000 |
| 7:142130947:G:GT | acceptor_gain | 1.0000 |
| 7:142130947:GG:G | acceptor_gain | 1.0000 |
| 7:142130947:GGA:G | acceptor_gain | 1.0000 |
| 7:142130947:GGATA:G | acceptor_gain | 1.0000 |
| 7:142131068:ACAGG:A | donor_loss | 1.0000 |
| 7:142131069:CAGG:C | donor_loss | 1.0000 |
| 7:142131070:AGGT:A | donor_loss | 1.0000 |
| 7:142131071:GGT:G | donor_loss | 1.0000 |
| 7:142131072:G:A | donor_loss | 1.0000 |
| 7:142131073:T:A | donor_loss | 1.0000 |
| 7:142132081:GTCTT:G | donor_gain | 1.0000 |
AlphaMissense
16690 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 7:142166155:T:A | W904R | 0.996 |
| 7:142166155:T:C | W904R | 0.996 |
| 7:142159326:T:A | W735R | 0.995 |
| 7:142159326:T:C | W735R | 0.995 |
| 7:142158249:T:C | F694L | 0.994 |
| 7:142158251:C:A | F694L | 0.994 |
| 7:142158251:C:G | F694L | 0.994 |
| 7:142171273:T:A | W1062R | 0.992 |
| 7:142171273:T:C | W1062R | 0.992 |
| 7:142166227:T:A | C928S | 0.991 |
| 7:142166228:G:C | C928S | 0.991 |
| 7:142166242:T:A | C933S | 0.991 |
| 7:142166243:G:C | C933S | 0.991 |
| 7:142172679:T:C | L1159P | 0.991 |
| 7:142137469:G:C | R295P | 0.990 |
| 7:142141084:T:A | W428R | 0.990 |
| 7:142141084:T:C | W428R | 0.990 |
| 7:142143823:T:A | W458R | 0.990 |
| 7:142143823:T:C | W458R | 0.990 |
| 7:142160207:G:C | R765P | 0.990 |
| 7:142164863:T:C | L831P | 0.990 |
| 7:142172688:G:C | R1162P | 0.990 |
| 7:142143825:G:C | W458C | 0.989 |
| 7:142143825:G:T | W458C | 0.989 |
| 7:142143826:T:A | W459R | 0.989 |
| 7:142143826:T:C | W459R | 0.989 |
| 7:142159328:G:C | W735C | 0.989 |
| 7:142159328:G:T | W735C | 0.989 |
| 7:142167476:T:C | L1006P | 0.989 |
| 7:142166157:G:C | W904C | 0.988 |
dbSNP variants (sampled 300 via entrez): RS1000021369 (7:142166786 C>G), RS1000038050 (7:142173128 A>G,T), RS1000043737 (7:142142835 A>C,G), RS1000068117 (7:142208024 T>C,G), RS1000068706 (7:142213860 A>T), RS1000106551 (7:142221641 T>A,C), RS1000113307 (7:142139573 A>G), RS1000142996 (7:142139753 A>G), RS1000170475 (7:142186181 A>T), RS1000289284 (7:142167725 G>A), RS1000352042 (7:142151368 G>A), RS1000389059 (7:142215089 G>A,C), RS1000418715 (7:142214106 AC>A), RS1000432738 (7:142154725 C>T), RS1000502906 (7:142184467 A>G,T)
Disease associations
OMIM: gene `` | disease phenotypes: MIM:142623
GenCC curated gene-disease
Mondo (1): Hirschsprung disease (MONDO:0018309)
Orphanet (1): Hirschsprung disease (Orphanet:388)
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004643_1 | 1,5-anhydroglucitol levels | 4.000000e-12 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0008009 | 1,5 anhydroglucitol measurement |
MeSH disease descriptors (1)
| Descriptor | Name | Tree numbers |
|---|---|---|
| D006627 | Hirschsprung Disease | C06.198.439; C06.405.469.158.701.439; C16.131.314.439 |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL3833502 (PROTEIN FAMILY)
Molecules with ChEMBL bioactivity
4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 133,604 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).
| Molecule | Name | Phase | Patents |
|---|---|---|---|
| CHEMBL404271 | ACARBOSE | 4 | 16 |
| CHEMBL50 | QUERCETIN | 3 | 74,559 |
| CHEMBL85398 | THIAZOLIDINEDIONE | 3 | 54,290 |
| CHEMBL307429 | DUVOGLUSTAT | 2 | 4,739 |
PharmGKB: 1 entry (VIP=true, CPIC=false)
ChEMBL bioactivities
434 potent at pChembl≥5 of 731 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).
PubChem BioAssay actives
400 with measured affinity, of 871 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.
| Compound | Assay | Type | Value | Unit |
|---|---|---|---|---|
| (1R,2R,14R,17R,18R,21S,24R,25R,26R)-2,13,13,17,18-pentamethyl-24-prop-1-en-2-yl-11-azaheptacyclo[15.11.0.02,14.04,12.05,10.018,26.021,25]octacosa-4(12),5,7,9-tetraene-21-carboxylic acid | 2005243: Inhibition of alpha glucosidase (unknown origin) measured after 60 mins | ic50 | 0.0400 | uM |
| 3-[4-[(2,4-dichlorophenyl)-[4-[[(2,4-dichlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-bromophenyl)-[4-[4-[[(3-bromophenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(2,4-dichlorophenyl)-[4-[4-[[(2,4-dichlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-methylphenyl)-[4-[4-[[(4-methylphenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-chlorophenyl)-[4-[[(4-chlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-nitrophenyl)-[4-[4-[[(4-nitrophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(2,4-dichlorophenyl)-[4-[4-[[(2,4-dichlorophenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-bromophenyl)-[4-[[(3-bromophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-chlorophenyl)-[4-[4-[[(3-chlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-methoxyphenyl)-[4-[4-[[(3-methoxyphenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-chlorophenyl)-[4-[4-[[(4-chlorophenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-bromophenyl)-[4-[4-[[(3-bromophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[[4-(dimethylamino)phenyl]-[4-[4-[[[4-(dimethylamino)phenyl]-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-methylphenyl)-[4-[[(4-methylphenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-nitrophenyl)-[4-[4-[[(4-nitrophenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-methoxyphenyl)-[4-[[(3-methoxyphenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[[4-(dimethylamino)phenyl]-[4-[[[4-(dimethylamino)phenyl]-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(3-chlorophenyl)-[4-[[(3-chlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-bromophenyl)-[4-[4-[[(4-bromophenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-fluorophenyl)-[4-[[(4-fluorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[[4-(dimethylamino)phenyl]-[4-[4-[[[4-(dimethylamino)phenyl]-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-methylphenyl)-[4-[4-[[(4-methylphenyl)-[5-(2-oxochromen-3-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenoxy]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-bromophenyl)-[4-[4-[[(4-bromophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-nitrophenyl)-[4-[[(4-nitrophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| 3-[4-[(4-chlorophenyl)-[4-[4-[[(4-chlorophenyl)-[5-(2-oxochromen-4-yl)-2-sulfanylidene-1,3,4-oxadiazol-3-yl]methyl]amino]phenyl]anilino]methyl]-5-sulfanylidene-1,3,4-oxadiazol-2-yl]chromen-2-one | 1509489: Inhibition of alpha-glucosidase (unknown origin) using p-nitro phenyl glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0700 | uM |
| S-(5-methyl-1,3,4-thiadiazol-2-yl) 5-(3-fluorophenyl)furan-2-carbothioate | 1951122: Inhibition of alpha glucosidase (unknown origin) | ic50 | 0.0820 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(4-methylphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(2-methylphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(4-methoxyphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(2-methoxyphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(3-methoxyphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(2-chlorophenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(4-chlorophenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(3,4-dimethylphenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(2,6-dimethylphenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(2,4-dimethylphenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-3-(3,5-dimethylphenyl)-5-[(4-fluorophenyl)methylidene]-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| N-[(Z)-[(5Z)-5-[(4-fluorophenyl)methylidene]-3-(3-methylphenyl)-4-oxo-1,3-thiazolidin-2-ylidene]amino]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.0900 | uM |
| 3-methyl-N-[4-methyl-3-(2,4,5-trichlorophenyl)-1,3-thiazol-2-ylidene]benzamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N-[4-methyl-3-(2,4,5-trichlorophenyl)-1,3-thiazol-2-ylidene]-2-oxochromene-3-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(2-bromophenyl)sulfonyl-3-[[5-[[(2-bromophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(2,5-dichlorophenyl)sulfonyl-3-[[5-[[(2,5-dichlorophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(2-chlorophenyl)sulfonyl-3-[[5-[[(2-chlorophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| 4-methoxy-N-[4-methyl-3-(2,4,5-trichlorophenyl)-1,3-thiazol-2-ylidene]benzamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| 3-[(4-methylphenyl)-[5-[[(4-methylphenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]methyl]-N’-(4-methylphenyl)sulfonyl-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(3,4-dichlorophenyl)sulfonyl-3-[[5-[[(3,4-dichlorophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(3,5-dichlorophenyl)sulfonyl-3-[[5-[[(3,5-dichlorophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N-[4-methyl-3-(2,4,5-trichlorophenyl)-1,3-thiazol-2-ylidene]furan-2-carboxamide | 1509481: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 5 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
| N’-(2,4-dichlorophenyl)sulfonyl-3-[[5-[[(2,4-dichlorophenyl)sulfonylamino]carbamoyl]-1H-indol-3-yl]-(4-methylphenyl)methyl]-1H-indole-5-carbohydrazide | 1509465: Inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-d-glucopyranoside as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins | ic50 | 0.1000 | uM |
CTD chemical–gene interactions
8 total (human), top 8 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | affects methylation, decreases expression | 3 |
| 2-methyl-4-isothiazolin-3-one | increases expression | 1 |
| benzo(e)pyrene | increases methylation | 1 |
| Methapyrilene | increases methylation | 1 |
| N-Nitrosopyrrolidine | decreases expression | 1 |
| Tobacco Smoke Pollution | increases expression | 1 |
| Tretinoin | increases expression | 1 |
| Okadaic Acid | decreases expression | 1 |
ChEMBL screening assays
136 unique, capped per target: 136 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL4135956 | Binding | Inhibition of alpha-glucosidase (unknown origin) at 400 uM using p-NPG as substrate pretreated for 10 mins followed by substrate addition measured after 5 mins | Bioactive Asarone-Derived Phenylpropanoids from the Rhizome of Acorus tatarinowii Schott. — J Nat Prod |
Clinical trials (associated diseases)
53 trials via MONDO — disease-level, not drug-specific.
| Trial | Phase | Status | Title |
|---|---|---|---|
| NCT02343562 | PHASE4 | UNKNOWN | Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis |
| NCT07186647 | PHASE4 | COMPLETED | Laparoscopic-Assisted Transanal Pull-Through for Hirschsprung Disease in Pediatric:Short and Intermediate Outcomes of Two Different Techniques |
| NCT03660176 | PHASE3 | UNKNOWN | Effects of Butyrate Enemas on Postoperative Intestinal Mobility Disorders in Hirschsprung’s Disease |
| NCT04904081 | PHASE3 | UNKNOWN | Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery |
| NCT00630838 | PHASE2 | COMPLETED | Probiotic Prophylaxis of Hirschprung’s Disease Associated Enterocolitis (HAEC) |
| NCT00671684 | PHASE1/PHASE2 | UNKNOWN | Endoscopic Mucosal Resection (EMR) for Diagnosis of Hirschsprung’s Disease |
| NCT01985646 | EARLY_PHASE1 | COMPLETED | A Trial on Conservative Treatment for Infants’ Hirschsprung Disease |
| NCT00478712 | Not specified | RECRUITING | Hirschsprung Disease Genetic Study |
| NCT01515501 | Not specified | COMPLETED | Endoscopic Mucosal Resection for the Diagnosis of a-Ganglionosis, a Controlled Prospective Trial (EDGE Trial) |
| NCT01793168 | Not specified | RECRUITING | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
| NCT01927809 | Not specified | UNKNOWN | Genetic Mosaicism in Hirschsprung’s Disease |
| NCT02193685 | Not specified | UNKNOWN | Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease |
| NCT02216994 | Not specified | UNKNOWN | A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis –a Prospective Study |
| NCT02296008 | Not specified | COMPLETED | 3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders |
| NCT02776176 | Not specified | UNKNOWN | Enhanced Recovery After Surgery In Hirschsprung Disease |
| NCT02857205 | Not specified | COMPLETED | MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung’s Associated EnteroColitis |
| NCT03269812 | Not specified | UNKNOWN | Laparoscopic Assisted Pull-through Versus Other Surgical Procedures for Treatment of Hirschsprung Disease |
| NCT03406741 | Not specified | COMPLETED | Neuropsychological Development and Functional Outcome Sin Children With Hirschsprung Disease at School Age |
| NCT03626350 | Not specified | ACTIVE_NOT_RECRUITING | Prospective Evaluation of the Efficacy and Safety of Submucosal Endoscopy |
| NCT03666767 | Not specified | COMPLETED | Management and Outcomes of Congenital Anomalies in Low-, Middle- and High-Income Countries |
| NCT04020939 | Not specified | COMPLETED | The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery. |
| NCT04106947 | Not specified | UNKNOWN | Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations |
| NCT04149093 | Not specified | UNKNOWN | The Association Between Calretinin and the Function of Ganglion Cells in Hirschsprung Disease |
| NCT04150120 | Not specified | COMPLETED | eHealth as an Aid for Facilitating and Supporting Self-management in Families With Long-term Childhood Illness |
| NCT04213976 | Not specified | UNKNOWN | Ostomy in Continuity or Conventional Ileostomy: a Retrospective Multicentric Analysis |
| NCT04476225 | Not specified | COMPLETED | Induced Pluripotent Stem Cells for Disease Research |
| NCT04598841 | Not specified | COMPLETED | Nutrition Support for Hirschsprung Disease |
| NCT04622410 | Not specified | RECRUITING | Registry for Hirschsprung Disease of the BELAPS |
| NCT04624334 | Not specified | TERMINATED | Non-invasive Assessment of Colonic Motility |
| NCT04713085 | Not specified | COMPLETED | Sacral Neuromodulation in Children and Adolescents |
| NCT04730128 | Not specified | COMPLETED | Translation and Validation of a Disease-specific Questionnaire for Hirschsprung’s Disease in Danish Patients |
| NCT04837963 | Not specified | COMPLETED | Does Hirschsprung Disease Increase the Risk of Febrile Urinary Tract Infection in Children |
| NCT04957667 | Not specified | COMPLETED | Scintigraphic Defecography for Evaluation of Functional Outcome in an Adult Hirschsprung Population |
| NCT05038345 | Not specified | TERMINATED | Hirschsprung Disease Trends in the United States: Analysis of the National Inpatient Sample |
| NCT05044741 | Not specified | COMPLETED | Risk Factors of Perforated HSCR in Neonates |
| NCT05293353 | Not specified | UNKNOWN | Neokare Safety and Tolerability Assessment in Neonates With GI Problems |
| NCT05307419 | Not specified | UNKNOWN | Full Thickness vs. Rectal Suction Biopsy in the Diagnosis of Hirschsprungs Disease |
| NCT05450991 | Not specified | RECRUITING | Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung’s Disease and Anorectal Malformations |
| NCT05655845 | Not specified | UNKNOWN | Risk Factors for Bowel Dysfunction at Preschool and Early Childhood Age in Children With Hirschsprung Disease |
| NCT06072976 | Not specified | RECRUITING | The Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies |
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): Hirschsprung disease